BibTex RIS Cite

OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi

Year 2013, Volume: 16 Issue: 4, 0 - 0, 01.10.2013

Abstract

Amaç: Bu çalışmada over tümörü tanısı alan hastalarda serum
VEGF (vasküler endotelyal büyüme faktörü) düzeyinin serum fibrinojen,
D-dimer ve tümör markerları düzeyleri ile korelasyonu ve bu hastalarda
diagnostik ve prognostik değerinin değerlendirilmesi amaçlanmıştır.

Materyal-Metod: Over tümörü ön tanısıyla opere olan 68 hastanın
preoperatif serum VEGF, fibrinojen, D-dimer ve tümör markerları
(Ca-125, Ca 19-9, Ca 15-3, CEA) düzeyleri belirlendi. 30 hasta epitelyal
over kanseri, 38 hasta benign over tümörü tanısı aldı. Serum VEGF
düzeylerinin tümör markerları, fibrinojen ve D-dimer düzeyleriyle
ilişkisi analiz edildi.
Sonuçlar: Epitelyal over kanseri grubunda benign over tümörü
grubuna göre serum VEGF düzeyleri anlamlı olarak daha yüksekti.
Serum VEGF düzeyinin 167 pg/ml cut-off değerinde over kanseri tanısında
sensitivite, spesifite, pozitif prediktif değer ve negatif prediktif
değeri sırasıyla %70, %68.4, %63.6 ve %72.4 olarak belirlendi. Epitelyal
over kanseri grubunda preoperatif serum VEGF değeri ile Ca125,
Ca 19-9, Ca 15-3, CEA, D-dimer, ve fibrinojen değerleri arasında
ilişki saptanmadı (p>0.05). Cox regresyon analizi sonuçları cut-off de-
ğeri üzerindeki serum VEGF düzeylerinin daha kısa survi ile korele
olduğunu gösterdi.
Tartışma: Bu verilere göre malign over tümörlerini ayırt etmede
serum VEGF düzeyleri yararlı bir serolojik biomarker olarak kullanı-
labilir. 167 pg/ml üzerindeki VEGF düzeyleri kanser sebepli ölüm
için bağımsız risk faktörü olarak değerlendirilebilir

References

  • 1. Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest. 2002;54(3):132-6.
  • 2. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-9.
  • 3. Ma Y, Qian Y, Lv W. The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. J Int Med Res. 2007;35(5):678- 84.
  • 4. Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):12-27.
  • 5. Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost. 2006;12(1):3-8.
  • 6. Oehler MK, Caffier H. Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Res. 1999;19(4A):2519-22.
  • 7. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19(2B):1401-5.
  • 8. Fasciani A, D’Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril. 2001;75(6):1218-21.
  • 9. Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S et al. Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet. 2003;83(1):53-8.
  • 10. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193-7.
  • 11. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512-7.
  • 12. Dehaven K, Taylor DD, Gercel-Taylor C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer. 2002;12(6):715-9.
  • 13. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006;16 Suppl 1:183-9.
  • 14. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77(3):456-61
  • 15. Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Weiss C et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol.1997;66(1):85-8.
Year 2013, Volume: 16 Issue: 4, 0 - 0, 01.10.2013

Abstract

Background: The present study aimed to analyze the correlation
of serum vascular endothelial growth factor (VEGF) with fibrinogen,
D-dimer and tumor markers in patients with ovarian mass and to
evaluate its diagnostic and prognostic value in these patients.
Materials and Methods: Preoperative serum VEGF, fibrinogen,
D-dimer levels and tumor markers (Ca 125, Ca19-9, Ca 15-3, CEA)
were assessed in 30 women with epithelial ovarian cancer (EOC) and
38 women with benign ovarian tumors. VEGF concentration was
determined by enzyme-linked immunosorbent assay (ELISA). The
correlations of serum VEGF with Ca 125, Ca19-9, Ca 15-3, CEA, Ddimer
and fibrinogen were also analyzed.
Results: Serum VEGF levels in patients with EOC were significantly
higher than those with benign ovarian mass. At a cut-off of 167
pg/ml; the sensitivity, specificity, positive predictive value and negative
predictive values of serum VEGF levels for diagnosing ovarian
carcinoma were 70%, 68.4%, 63.6% and 72.4%, respectively. No significant
correlation was found between preoperative serum VEGF and
Ca 125, Ca19-9, Ca 15-3, CEA, D-dimer and fibrinogen levels in the
EOC group (p>0.05). Cox regression analysis showed that serum
VEGF level over the cut-off value was correlated with shorter survival
(p<0.001).
Conclusion: These data suggest that VEGF may be a useful serological
biomarker in differentiating benign adnexal masses from EOC.
Preoperative VEGF levels >167 pg/ml are an independent risk factor
for cancer related death.

References

  • 1. Candido Dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest. 2002;54(3):132-6.
  • 2. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-9.
  • 3. Ma Y, Qian Y, Lv W. The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma. J Int Med Res. 2007;35(5):678- 84.
  • 4. Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):12-27.
  • 5. Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost. 2006;12(1):3-8.
  • 6. Oehler MK, Caffier H. Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Res. 1999;19(4A):2519-22.
  • 7. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19(2B):1401-5.
  • 8. Fasciani A, D’Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril. 2001;75(6):1218-21.
  • 9. Demirkiran F, Kumbak B, Bese T, Arvas M, Benian A, Aydin S et al. Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet. 2003;83(1):53-8.
  • 10. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193-7.
  • 11. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512-7.
  • 12. Dehaven K, Taylor DD, Gercel-Taylor C. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer. 2002;12(6):715-9.
  • 13. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006;16 Suppl 1:183-9.
  • 14. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77(3):456-61
  • 15. Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Weiss C et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol.1997;66(1):85-8.
There are 15 citations in total.

Details

Other ID JA45TP42TN
Journal Section Research Article
Authors

Mesut Mısıroğlu This is me

Özlem Altınkaya This is me

Ebru Zülfikaroğlu This is me

Aylin Sağlam This is me

Tayfun Güngör This is me

Publication Date October 1, 2013
Submission Date October 1, 2013
Published in Issue Year 2013 Volume: 16 Issue: 4

Cite

APA Mısıroğlu, M., Altınkaya, Ö., Zülfikaroğlu, E., Sağlam, A., et al. (2013). OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi. Türk Jinekolojik Onkoloji Dergisi, 16(4).
AMA Mısıroğlu M, Altınkaya Ö, Zülfikaroğlu E, Sağlam A, Güngör T. OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi. TRSGO Dergisi. October 2013;16(4).
Chicago Mısıroğlu, Mesut, Özlem Altınkaya, Ebru Zülfikaroğlu, Aylin Sağlam, and Tayfun Güngör. “OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi”. Türk Jinekolojik Onkoloji Dergisi 16, no. 4 (October 2013).
EndNote Mısıroğlu M, Altınkaya Ö, Zülfikaroğlu E, Sağlam A, Güngör T (October 1, 2013) OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi. Türk Jinekolojik Onkoloji Dergisi 16 4
IEEE M. Mısıroğlu, Ö. Altınkaya, E. Zülfikaroğlu, A. Sağlam, and T. Güngör, “OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi”, TRSGO Dergisi, vol. 16, no. 4, 2013.
ISNAD Mısıroğlu, Mesut et al. “OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi”. Türk Jinekolojik Onkoloji Dergisi 16/4 (October 2013).
JAMA Mısıroğlu M, Altınkaya Ö, Zülfikaroğlu E, Sağlam A, Güngör T. OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi. TRSGO Dergisi. 2013;16.
MLA Mısıroğlu, Mesut et al. “OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi”. Türk Jinekolojik Onkoloji Dergisi, vol. 16, no. 4, 2013.
Vancouver Mısıroğlu M, Altınkaya Ö, Zülfikaroğlu E, Sağlam A, Güngör T. OVER TÜMÖRLERİNDE SERUM VEGF DÜZEYİNİN DİAGNOSTİK VE PROGNOSTİK DEĞERi. TRSGO Dergisi. 2013;16(4).